Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2019

17.07.2019 | short review

Checkpoint inhibitors in head and neck cancer

verfasst von: Dr. Ilson Sepulveda, Rodrigo Ascui, A. Andrés Capizzano

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Head and neck cancer (HNC) are aggressive cancers and represents the sixth leading cancer by incidence worldwide. This kind of cancer constitutes about 3% of all newly diagnosed malignant tumors in humans, and this percentage is likely to increase in the future. Most common available treatment methods which include surgery, radiotherapy, and chemotherapy are associated with low survival outcomes in combination with substantial toxicities emphasize the necessity for novel treatment strategies.The combination immunotherapies represent a fundamental step in the progress towards improving responses, and immune checkpoint inhibitors will likely become the immunotherapeutic backbone of future cancer treatments.
Literatur
1.
Zurück zum Zitat Guidi A, Codecà C, Ferrar D. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol. 2018;35(3):37. CrossRef Guidi A, Codecà C, Ferrar D. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol. 2018;35(3):37. CrossRef
2.
Zurück zum Zitat Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treat Rev. 2018;65:78–86. CrossRef Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treat Rev. 2018;65:78–86. CrossRef
3.
Zurück zum Zitat Fuereder T. Immunotherapy for head and neck squamous cell carcinoma. Memo. 2016;9:66–9. CrossRef Fuereder T. Immunotherapy for head and neck squamous cell carcinoma. Memo. 2016;9:66–9. CrossRef
4.
Zurück zum Zitat Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. CrossRef Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. CrossRef
5.
Zurück zum Zitat Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013;73(4):315–25. CrossRef Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013;73(4):315–25. CrossRef
6.
Zurück zum Zitat Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol. 2016;61:152–8. CrossRef Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol. 2016;61:152–8. CrossRef
7.
Zurück zum Zitat Pai SI. Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. Oncoimmunology. 2013;2(5):e24065. CrossRef Pai SI. Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. Oncoimmunology. 2013;2(5):e24065. CrossRef
9.
Zurück zum Zitat Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838–45. CrossRef Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838–45. CrossRef
10.
Zurück zum Zitat Bauml J, Seiwert TY, Gilbert J, Pfister DG, Worden F, Liu SV, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35:1542–9. CrossRef Bauml J, Seiwert TY, Gilbert J, Pfister DG, Worden F, Liu SV, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35:1542–9. CrossRef
11.
Zurück zum Zitat Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67. Jan. CrossRef Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67. Jan. CrossRef
12.
Zurück zum Zitat Cohen, ESMO 2017; September, 11; Madrid, Spain, Oral Presentation. 2017 Cohen, ESMO 2017; September, 11; Madrid, Spain, Oral Presentation. 2017
14.
Zurück zum Zitat Licitra LF, Haddad RI, Even C, et al. EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15):6012–6012. CrossRef Licitra LF, Haddad RI, Even C, et al. EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15):6012–6012. CrossRef
15.
Zurück zum Zitat Galluzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res. 2016;4:895–902. CrossRef Galluzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res. 2016;4:895–902. CrossRef
16.
Zurück zum Zitat Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048: Fase III study of first line pembroluzimab (P) for recurrent/metastasic head and neck squamous cell carcinoma (R/M HNSCC). ASCO. 2019;The ASCO Post Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048: Fase III study of first line pembroluzimab (P) for recurrent/metastasic head and neck squamous cell carcinoma (R/M HNSCC). ASCO. 2019;The ASCO Post
17.
Zurück zum Zitat Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 2015;365:23–9. CrossRef Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 2015;365:23–9. CrossRef
18.
Zurück zum Zitat Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123:2756–63. CrossRef Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123:2756–63. CrossRef
19.
Zurück zum Zitat Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15:927–43. CrossRef Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15:927–43. CrossRef
21.
Zurück zum Zitat Sacco AG, Chen R, Ghosh D, et al. An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis. J Clin Oncol. 2019;37(suppl):Abstr 6033 CrossRef Sacco AG, Chen R, Ghosh D, et al. An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis. J Clin Oncol. 2019;37(suppl):Abstr 6033 CrossRef
22.
Zurück zum Zitat Adkins D, et al. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Lancet Oncol. 2018;19:1082–93. CrossRef Adkins D, et al. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Lancet Oncol. 2018;19:1082–93. CrossRef
Metadaten
Titel
Checkpoint inhibitors in head and neck cancer
verfasst von
Dr. Ilson Sepulveda
Rodrigo Ascui
A. Andrés Capizzano
Publikationsdatum
17.07.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0511-8